What does PATHOMATION do?

PATHOMATION is an IT company in Antwerpen. Private Limited, started on 8 November 2012, 1 establishment.

What is the address of PATHOMATION?

The registered office of PATHOMATION is located at Prinses Joséphine Charlottelaan 10, 2600 Antwerpen.

Is PATHOMATION still active?

Yes. According to the CBE (30 October 2026) PATHOMATION is active, legal situation “Normale toestand”, started on 8 November 2012.

Is PATHOMATION registered on Peppol?

Yes, PATHOMATION is registered on the Peppol network with ID 0208:0500694204.

What is the enterprise number of PATHOMATION?

The enterprise number of PATHOMATION is BE0500694204.

When was PATHOMATION founded?

PATHOMATION was founded on 8 November 2012.

Who are the directors of PATHOMATION?

According to the 2025 annual accounts, the directors of PATHOMATION are: Histodig BV, Heitbrink Teixidor SL, CellCarta NV, Kockx-Consulting BV.

Is PATHOMATION a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 November 2012; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did PATHOMATION make in 2025?

PATHOMATION recorded a loss after taxes of € 402,294 in financial year 2025.

What is the revenue of PATHOMATION?

As a small company, PATHOMATION is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 568,228.

How much does an employee at PATHOMATION earn?

The average wage cost per full-time employee at PATHOMATION was € 83,400 in 2025: staff costs of € 617,444 for 7.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PATHOMATION have?

According to the 2025 annual accounts, PATHOMATION has 7.4 full-time equivalents (FTE).

PATHOMATION (Private Limited) - Antwerpen - BE0500694204

Dossier PATHOMATION, printed on 30 October 2026 from databakkes.be/en/0500694204/pathomation. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PATHOMATION from Antwerpen, company number BE0500694204, closed financial year 2025 with a result of € -402,294 after tax. For that financial year PATHOMATION recorded a gross margin of € 568,228 and equity of € 890,585. Compared with financial year 2024, the result moved from € 7,002 to € -402,294. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.

What it is worth Healthy

€ 890,585

▼ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -402,294

▼ still € 7,002 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 109,401

▼ 88% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 665.

People and assets in 2025

Full-time equivalents

7.4

▲ 2.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 617,444

▲ 51% vs 2024

€ 83,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,082

▲ € 16,069 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 116,181

▼ 45% vs 2024

€ 20,767 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 78,646

▼ 85% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 66,481

▲ 21% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 445,114 Gross margin 2022: € 445,114 First fiscal year in the series	€ 739,917 Gross margin 2023: € 739,917 ▲ 66% vs 2022 (€ 445,114) Favourable step	€ 684,218 Gross margin 2024: € 684,218 ▼ 8% vs 2023 (€ 739,917) Unfavourable step	€ 568,228 Gross margin 2025: € 568,228 ▼ 17% vs 2024 (€ 684,218) Unfavourable step	▼ 17%
Profit after taxes	€ -125,164 Profit after taxes 2022: € -125,164 First fiscal year in the series	€ 105,141 Profit after taxes 2023: € 105,141 ▲ € 230,305 vs 2022 (€ -125,164) Favourable step	€ 7,002 Profit after taxes 2024: € 7,002 ▼ 93% vs 2023 (€ 105,141) Unfavourable step	€ -402,294 Profit after taxes 2025: € -402,294 ▼ € 409,296 vs 2024 (€ 7,002) Unfavourable step	▼ € 409,296
Equity	€ 380,816 Equity 2022: € 380,816 First fiscal year in the series	€ 485,957 Equity 2023: € 485,957 ▲ 28% vs 2022 (€ 380,816) Favourable step	€ 1,292,879 Equity 2024: € 1,292,879 ▲ 166% vs 2023 (€ 485,957) Favourable step	€ 890,585 Equity 2025: € 890,585 ▼ 31% vs 2024 (€ 1,292,879) Unfavourable step	▼ 31%
Total debts	€ 537,401 Total debts 2022: € 537,401 First fiscal year in the series	€ 566,082 Total debts 2023: € 566,082 ▲ 5% vs 2022 (€ 537,401) Unfavourable step	€ 1,355,539 Total debts 2024: € 1,355,539 ▲ 139% vs 2023 (€ 566,082) Unfavourable step	€ 808,477 Total debts 2025: € 808,477 ▼ 40% vs 2024 (€ 1,355,539) Favourable step	▼ 40%
Cash	€ 30,552 Cash 2022: € 30,552 First fiscal year in the series	€ 40,518 Cash 2023: € 40,518 ▲ 33% vs 2022 (€ 30,552) Favourable step	€ 912,228 Cash 2024: € 912,228 ▲ € 871,711 vs 2023 (€ 40,518) Favourable step	€ 109,401 Cash 2025: € 109,401 ▼ 88% vs 2024 (€ 912,228) Unfavourable step	▼ 88%
Land & buildings	€ 3,397 Land & buildings 2022: € 3,397 First fiscal year in the series	-	-	-
Retained profit	€ 290,816 Retained profit 2022: € 290,816 First fiscal year in the series	€ 395,957 Retained profit 2023: € 395,957 ▲ 36% vs 2022 (€ 290,816) Favourable step	€ 402,959 Retained profit 2024: € 402,959 ▲ 2% vs 2023 (€ 395,957) Favourable step	€ 665 Retained profit 2025: € 665 ▼ € 402,294 vs 2024 (€ 402,959) Unfavourable step	▼ € 402,294
Bank debt	€ 158,773 Bank debt 2022: € 158,773 First fiscal year in the series	€ 124,727 Bank debt 2023: € 124,727 ▼ 21% vs 2022 (€ 158,773) Favourable step	€ 211,383 Bank debt 2024: € 211,383 ▲ 69% vs 2023 (€ 124,727) Unfavourable step	€ 116,181 Bank debt 2025: € 116,181 ▼ 45% vs 2024 (€ 211,383) Favourable step	▼ 45%
Balance sheet total	€ 918,216 Balance sheet total 2022: € 918,216 First fiscal year in the series	€ 1,052,039 Balance sheet total 2023: € 1,052,039 ▲ 15% vs 2022 (€ 918,216) Unchanged	€ 2,648,418 Balance sheet total 2024: € 2,648,418 ▲ 152% vs 2023 (€ 1,052,039) Unchanged	€ 1,699,061 Balance sheet total 2025: € 1,699,061 ▼ 36% vs 2024 (€ 2,648,418) Unchanged	▼ 36%
Employees (FTE)	4.8 Employees (FTE) 2022: 4.8 First fiscal year in the series	4.9 Employees (FTE) 2023: 4.9 ▲ 0.1 vs 2022 (4.8) Unchanged	5.2 Employees (FTE) 2024: 5.2 ▲ 0.3 vs 2023 (4.9) Unchanged	7.4 Employees (FTE) 2025: 7.4 ▲ 2.2 vs 2024 (5.2) Unchanged	▲ 2.2

Key figures of PATHOMATION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PATHOMATION?

What happened at PATHOMATION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 16, 2026 New annual accounts for financial year 2025: loss of € 402,294 (▼ € 409,296 vs 2024). Source: NBB ↗
2026 Heitbrink Teixidor SL became a director. NBB
2026 CellCarta NV became a director. NBB
2026 Kockx-Consulting BV stepped down as director. NBB
Nov 8, 2012 New establishment in Antwerpen. KBO
Nov 8, 2012 Start of the company according to the CBE. KBO

In short

From € 125,164 loss in 2022 to € 402,294 loss in 2025.

Paid € 10,766 in corporate taxes since 2022.

Best year ever: 2023, with € 105,141 profit.

On average € 76,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

CellCarta 18.5%

The stake of CellCarta comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PATHOMATION

Behind PATHOMATION are Histodig BV, Heitbrink Teixidor SL and CellCarta NV. The shares are held by CellCarta (18.5%).

Directors

According to the 2025 annual accounts

Histodig BV

Director · represented by Wim Waelput

Also active at: AGOKO

Heitbrink Teixidor SL

Director · represented by Filip Heitbrink

since 2026

CellCarta NV

Director · represented by Yannick Waumans

Owns 3.1% via CellCarta

since 2026

Kockx-Consulting BV

Director · represented by Mark Kockx

Also active at: BATYO, CellCarta, HistoGeneX Holding, Arsenal IO Belgium

· until 2026

Shareholders

CellCarta · holding of CellCarta NV

18.5%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Prinses Joséphine Charlottelaan 10

2600 Antwerpen

2.215.005.193

Sint-Bavostraat 78-80

2610 Antwerpen

Active since 8 November 2012

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0500.694.204

VAT number

BE 0500.694.204

Registered office

Prinses Joséphine Charlottelaan 10, 2600 Antwerpen

Names & denominations

PATHOMATION

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

8 November 2012

Peppol

Active · Active since 4 Apr 2025

Activities · NACE

Ontwerpen van computerprogramma’s

Ontwerpen en programmeren van computerprogramma's

Activiteiten op het gebied van computerconsultancy en beheer van computerfaciliteiten

Computerconsultancy-activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

PATHOMATION

Financials

What happened to PATHOMATION?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions